Welcome to our dedicated page for Bioadaptives news (Ticker: BDPT), a resource for investors and traders seeking the latest updates and insights on Bioadaptives stock.
BioAdaptives, Inc. (BDPT) news covers the company’s activity in nutraceuticals, nootropics, weight management, and pet wellness. Recent announcements highlight product launches, clinical milestones, and third-party validations that shape BioAdaptives’ position in the health and wellness market.
Investors and followers can track updates on MyndMed™, a cognitive-support dietary supplement formulated to aid memory, focus, and mental clarity. News items describe its commercial launch, manufacturing in cGMP-certified facilities, third-party testing, and clearance from TruShield™ Laboratory Services confirming compliance with World Anti-Doping Agency (WADA) standards, which is particularly relevant for competitive athletes and sports organizations.
Coverage also includes developments around NeuroRush™, an adaptogenic nootropic intended to support cognitive performance and stress resilience, and Zeranovia™, a weight management product undergoing IRB-approved human clinical trials and dosage studies. These updates provide insight into BioAdaptives’ research progress, trial outcomes, and product rollout plans.
On the pet wellness side, news features the PawPa™ division and products such as Pawpa™ Regen and Regen Dog Chews, which are described as supporting stem cell activation and regenerative healing in aging dogs. Articles detail veterinarian trials, the APBAR® rating system, and national launch plans.
Visitors to this BDPT news page can review company press releases regarding leadership appointments, advisory board additions, and strategic direction, alongside product-focused announcements. For those monitoring the nutraceutical and wellness sector, this feed offers a centralized view of BioAdaptives’ latest product introductions, clinical steps, and validation efforts.
BioAdaptives, Inc. (OTCMkts: BDPT) has initiated a study of its Lung Armor™ package, which includes the Lung Cleanser™ device and PrimiLungs™ supplement, targeting respiratory health in long-term smokers and those exposed to second-hand smoke. The Lung Cleanser™ is an FDA-cleared medical device aimed at enhancing lung clearance. Research will evaluate user experience and potential improvements in product efficacy, with initial studies planned in the US and possibly Eastern Europe. The company seeks to provide daily support for smokers’ breathing and health through its innovative products.
BioAdaptives (OTCMkts: BDPT) announced a Letter of Intent to acquire U.S. Patent 9,783,432B from inventor Thomas J. Mohr. This patent covers a revolutionary technology that enhances water's ability to retain oxygen, providing longer-term health benefits compared to traditional oxygenated water. CEO Edward Jacobs emphasized the potential advantages of the new product, which may improve endurance and overall wellness. While the financial terms are still being negotiated, the deal involves cash, royalties, and warrants. BioAdaptives aims to expand its product line with this innovative technology.
BioAdaptives (OTC: BDPT) has entered a Marketing Agreement with Acoustic Innovations LLC for the LungFlute™ device, which is FDA-cleared and supports lung health and diagnosis of pulmonary diseases. The agreement grants BioAdaptives marketing rights across the US, Canada, and other approved regions. The LungFlute™ aids in mucus clearance and is expected to enhance TB diagnosis in an $800,000 trial in Africa. BioAdaptives plans to promote the device alongside its PrimiLungs™ supplement in a new package called LungArmor™ aimed at improving lung hygiene and immune defense.
BioAdaptives, Inc. (OTCMkts: BDPT) announces a collaboration with Professor Lorrin Koran from Stanford Medical Center for research on PluriPain®, aimed at alleviating chronic pain linked to Gadolinium Deposition Disease. This rare disorder surfaces in patients exposed to gadolinium from MRI contrast agents, resulting in prolonged pain through inflammatory cytokine production. BioAdaptives will supply PluriPain® for this research, furthering its commitment to addressing inflammatory pain issues.
BioAdaptives (OTCMkts: BDPT) announced the launch of its Ambassador Program for the Livestock Impact Division, promoting products like Equine All-in-One™ and Canine Regen®. The program aims to enhance affiliate marketing through social media and discounts, targeting industry participants. Notably, Equine All-in-One™ is a plant-based supplement reported to improve horse health and performance, while Canine Regen® supports dog health and regeneration. The initiative will be led by COO Charles Townsend, with plans for national and potential international outreach.
BioAdaptives, Inc. (OTCMkts: BDPT) has entered a Licensing and Co-Marketing Agreement with The Fedr8tion Ltd., which has 11 million affiliate members. This partnership allows BioAdaptives to offer special membership pricing on its nutraceuticals through Fedr8tion’s platform, enhancing its reach to a new demographic within the e-gaming community. The collaboration aims to introduce BioAdaptives' natural supplement products to a younger audience engaged in e-sports, leveraging Fedr8tion's established member base and marketing capabilities.
BioAdaptives, Inc. (OTCMkts: BDPT) announces key executive appointments: Charles Townsend is appointed Chief Operating Officer and director, Robert W. Ellis remains President and becomes a director, and Ronald Lambrecht is reappointed Chief Financial Officer. Townsend brings over 30 years of experience from various sectors, including operations and enterprise marketing, enhancing the leadership team's strength. The company focuses on natural health products for humans and animals, emphasizing wellness and innovative formulations.
BioAdaptives, Inc. (OTCMkts: BDPT) has launched a new social media advertising campaign aimed at promoting its pain relief and immune-boosting products. Partnering with J Ramsdell Consulting and The Dropup Agency, the company will utilize targeted marketing through Click Funnels and social platforms like Facebook, Instagram, and YouTube. CEO Edward Jacobs highlighted years of research leading to advanced formulations, anticipating significant revenue growth from this initiative. The company manufactures natural health products, emphasizing pain relief and immune defense, with a commitment to holistic wellness.